Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Preliminary Efficacy and Safety Data of RG6125 in RA Patients with an Inadequate Response to TNF Inhibitors

Preliminary Efficacy and Safety Data of RG6125 in RA Patients with an Inadequate Response to TNF Inhibitors

Presented By
Uwe Junker, Roche Innovation Center Basel, Switzerland
Conference
EULAR 2019

RG6125, an anti-cadherin-11 monoclonal antibody was well-tolerated with only mild to moderate adverse events. However, RG6125 in combination with TNF inhibitor (TNFi) therapy did not show a discernible treatment effect in rheumatoid arthritis (RA) patients compared with placebo.

The protein cadherin-11, found on stromal cells in the joint, has been identified as a new target for RA treatment. Cadherin-11 is expressed on fibroblasts in joints of RA patients and increases local fibroblast-mediated inflammation, pannus formation, and tissue invasion. RG6125 is a new human monoclonal antibody directed against cadherin-11, and is believed to disrupt immune cell adhesion in a non-immunosuppressive manner.

Junker et al. aimed to assess the safety, tolerability, and efficacy of RG6125 as adjunctive treatment in patients with moderately to severely active RA and unresponsive to TNFi treatment. In this phase 2, multicentre, randomised, double-blind placebo-co...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on